VICTRELIS
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
May 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VICTRELIS is an oral capsule small-molecule protease inhibitor approved by Merck & Co. in May 2011. The drug's specific indication and mechanism of action are not disclosed in available data, though its oral formulation and capsule form suggest systemic disease treatment. As a first-generation protease inhibitor in its class, it established a key therapeutic position upon launch.
LOE Approaching1.0 years to LOE
Product faces steep commercial decline as loss-of-exclusivity approaches in late 2027; brand team likely focused on managed transition and cost-containment strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects
Started Oct 2011
32 enrolled
Healthy
Why This Matters for Your Career
Worked on VICTRELIS at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.